机构：[1]Department of pathology, The First Affiliated Hospital of Kunming Medical University, Yunnan, China.医技科室病理科昆明医科大学附属第一医院[2]Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, Yunnan, China.[3]Department of Clinical Laboratory, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Yunnan, China.[4]Department of Medical Oncology, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Yunnan, China.[5]Department of Organ Transplantation, The First Affiliated Hospital of Kunming Medical University, Yunnan, China外科科室器官移植中心昆明医科大学附属第一医院
Pancreatic cancer is associated with poor prognosis due to limited therapeutic options. Excision repair cross-complementing 3 (ERCC3) is an important member of nucleotide excision repair (NER) that is overexpressed in some cancers and may be regarded as a poor prognostic factor. Yet, its role in pancreatic cancer remains unclear. This study aimed to investigate the expression and functions of ERCC3 in pancreatic cancer patients and its relation with clinicopathological features. Our data suggested that the protein expression level of ERCC3 was higher in tumor tissues than in adjacent tissues. In addition, the expression of ERCC3 has shown to be associated with the tumor extent (p=0.035). Besides, analysis of the dataset in The Cancer Genome Atlas (TCGA) revealed that high expression of ERCC3 was associated with poor overall survival in pancreatic cancer patients (p=0.0136). In Cox regression analysis, ERCC3 was an independent prognostic factor for overall survival in pancreatic cancer (p<0.001). Furthermore, our in vitro data further suggested that the overexpression of ERCC3 significantly promoted pancreatic cancer (BxPC-3, CFPAC-1, and PANC-1 cells) proliferation, invasion, and migration. Taken together, this study suggested that high expression of ERCC3 might be a poor prognostic factor in human pancreatic cancer and might be used as a promising therapeutic target for pancreatic cancer treatment.
基金：
National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81660135, 81560037, 31960145, 81960462, 81760455, 31960200, 81460421, 31660246, 81760426]; Applied Basic Research Programs of Yunnan Provincial Department of Science and Technology [2019FB091, 2018FB120, 2018FE468(-001), 2018FE 001(-314)]
第一作者机构：[1]Department of pathology, The First Affiliated Hospital of Kunming Medical University, Yunnan, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of pathology, The First Affiliated Hospital of Kunming Medical University, Yunnan, China.[2]Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, Yunnan, China.[*1]Department of pathology, The First Affiliated Hospital of Kunming Medical University, No.295 Xichang Road, Wuhua District, Kunming 650032, Yunnan Province, China[*2]Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, No.1168 Yuhua Road, Chenggong District, Kunming 650500, Yunnan Province, China[*3]Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, No.1168 Yuhua Road, Chenggong District, Kunming 650500, Yunnan Province, China
推荐引用方式(GB/T 7714)：
Wang Shujie,Liu Wenjing,Ni Yueli,et al.Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer[J].JOURNAL OF CANCER.2021,12(9):2550-2559.doi:10.7150/jca.54576.
APA：
Wang, Shujie,Liu, Wenjing,Ni, Yueli,Wang, Lifeng,Zhu, Yuzhi...&Yang, Zhe.(2021).Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer.JOURNAL OF CANCER,12,(9)
MLA：
Wang, Shujie,et al."Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer".JOURNAL OF CANCER 12..9(2021):2550-2559
